Lysyl Oxidase Like-4 (LOXL4) as a tumor marker and prognosticator in advanced stage laryngeal cancer
Open Access
- 1 November 2022
- journal article
- research article
- Published by Elsevier BV in Brazilian Journal of Otorhinolaryngology
- Vol. 88 (6), 968-974
- https://doi.org/10.1016/j.bjorl.2021.02.009
Abstract
No abstract availableKeywords
Funding Information
- Hacettepe Üniversitesi
This publication has 19 references indexed in Scilit:
- A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder CancerClinical Cancer Research, 2013
- The molecular biology of head and neck cancerNature Reviews Cancer, 2010
- Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology ConsortiumCancer Epidemiology, Biomarkers & Prevention, 2009
- Recent Advances in Head and Neck CancerThe New England Journal of Medicine, 2008
- LOXL1 and LOXL4 Are Epigenetically Silenced and Can Inhibit Ras/Extracellular Signal-Regulated Kinase Signaling Pathway in Human Bladder CancerCancer Research, 2007
- Selective upregulation and amplification of the lysyl oxidase like‐4 (LOXL4) gene in head and neck squamous cell carcinomaThe Journal of Pathology, 2007
- The Tumor Suppressor Activity of the Lysyl Oxidase Propeptide Reverses the Invasive Phenotype of Her-2/neu–Driven Breast CancerCancer Research, 2007
- Lysyl oxidase is essential for hypoxia-induced metastasisNature, 2006
- Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human CancersPLoS Medicine, 2006
- Lysyl Oxidase Is a Tumor Suppressor Gene Inactivated by Methylation and Loss of Heterozygosity in Human Gastric CancersCancer Research, 2004